SML3679

SLM6031434 hydrochloride

≥98% (HPLC)

• Synonym(e): (2S)-2-[3-[4-(Octyloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-pyrrolidinecarboximidamide, hydrochloride, (S)-2-(3-(4-(Octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide, hydrochloride, (S)-Amino(2-(3-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)methaniminium chloride, SLM 6031434 HCl, SLM 6081442 (S)-enantiomer HCl, SLM-6031434 HCl, SLM-6081442 (S)-enantiomer HCl, SLM6081442 (S)-enantiomer HCl
• Empirische Formel (Hill-System): C₂₂H₃₀F₃N₅O₂·HCl
• CAS-Nummer: 1897379-34-8
• Molekulargewicht: 489.96
• MDL-Nummer: MFCD31689247
• UNSPSC-Code: 51111800
• UNSPSC-Code: 12352200
• NACRES: NA.21

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: desiccated
• Farbe: white to beige
• Löslichkeit: water: ≥2 mg/mL
• Lagertemp.: -10 to -25°C

Beschreibung

Biochem./physiol. Wirkung

SLM6031434 is a selective sphingosine (Sph) kinase 2 (SK2, SphK2, SpK2) inhibitor (r/m SphK2 Ki = 400/500 nM, r/m SphK1 Ki >20 μM) that effectively downregulates cellular sphingosine 1-phosphate (S1P) level (47% S1P & 143% Sph of control in U937 post 2h 100 nM SLM6031434 treatment) and selectively reduces plasma S1P in Sphk1-/-, but not Sphk2-/- mice in vivo (5 mg/kg i.v.). In contrary to Sphk2-KO mice, SLM6031434 treatment enhances plasma S1P in wild-type mice and offers neuroprotective efficacy against ischemic stroke (2 mg/kg i.v. 2h prior to tMCAO).

Vorsicht

Hygroscopic

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable